NOTIFICAÇÕES DE FARMACOVIGILÂNCIA SEGUNDO O VIGMED NO BRASIL

• DOI: https://doi.org/10.22533/at.ed.98924160114

• Palavras-chave: Medicamentos, Farmacovigilância, VigMed

• Keywords: Medicines, Pharmacovigilance, VigMed

• Abstract: The aim here is to provide an overview of the main pharmacovigilance notifications according to data available on the VigMed system in Brazil. This data is available on the website: https://www.gov.br/anvisa/pt-br/acessoainformacao/dadosabertos/informacoes-analiticas/notificacoes-de-farmacovigilancia. In general terms, the state of São Paulo has the highest number of notifications, 42,926 (27.62%), followed by Minas Gerais with 7,794 (5.02%). In terms of gender, females had the highest number of notifications, 92,266 (59.37%). The main age group involved is 18-44 years old, with 49,050 (31.56%) notifications. Health services and pharmacists were the main notifiers with 68,578 (44.13%) and 55,489 (35.71%), respectively. The main drugs with notifications were those related to AstraZeneca's Covid-19 vaccine with 13,644, Comirnaty with 8,706 and Coronavac with 4,624 notifications. With regard to the severity of adverse events, the majority, 38.53%, had a reported degree of severity, and the majority of the outcomes were recovered/resolved, 73,694 notifications. The main adverse event reported was Cafalea with 15,933 notifications, followed by Pruritus, 14,233, and Pyrexia with 12,740 notifications. It is important to know this data so that health managers, health professionals and public policy makers can take the necessary measures to reduce these events and improve the safety of the population.